Tanespimycin (KOS-953, 17-AAG)
| Brand Name: | |
| Generic Name: | tanespimycin |
| Code Names: | KOS-953, 17-AAG |
| Company: | Bristol-Myers Squibb / Kosan Biosciences |
| FDA Clinical Phase: | 3 |
Description:
A benzoquinone antineoplastic antibiotic derived from the antineoplastic antibiotic geldanamycin. Tanespimycin binds to and inhibits the cytosolic chaperone functions of heat shock protein 90 (HSP90). HSP90 maintains the stability and functional shape of many oncogenic signaling proteins; the inhibition of HSP90 promotes the proteasomal degradation of oncogenic signaling proteins that may be overexpressed by tumor cells.
Clinical Trials:
Currently, there are no open clinical trials studying tanespimycin for multiple myeloma.
Source:
NCI, Tanespimycin, http://www.ncipoet.com/Templates/drugdictionary.aspx?CdrID=43635 (as of May 22, 2009);
ClinicalTrials.gov, Multiple Myeloma AND Tanespimycin, http://www.clinicaltrial.gov/ct2/show/NCT00546780?term=multiple+myeloma+AND+Tanespimycin&rank=1 (as of November 14, 2009)
NCI, Tanespimycin, http://www.ncipoet.com/Templates/drugdictionary.aspx?CdrID=43635 (as of May 22, 2009);
ClinicalTrials.gov, Multiple Myeloma AND Tanespimycin, http://www.clinicaltrial.gov/ct2/show/NCT00546780?term=multiple+myeloma+AND+Tanespimycin&rank=1 (as of November 14, 2009)
Related Articles:
- Immune System Cells Protect Myeloma Cancer Cells, Study Finds
- Research Shows Velcade’s Possible Mechanism of Action
- New Myeloma Drugs Target Different Mechanisms: Misfolded Proteins
- Trial Investigates Effects Of Tanespimycin-Velcade Combination Treatment (ASCO 2009)
- Scientist Receives $720,000 Grant To Research New Myeloma Drug Targets
Leave a comment